| BID | 0.3700 | ASK | 0.4044 | ||
| Open | 0.4000 | Previous Close | 0.4001 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 3.00 | Analyst Rating | — 0.00 | |
| Potential % | 710.81 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/100/100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/100/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.44 | Earnings Rating | — | |
| Market Cap | 3.03M | Earnings Date | - | |
| Alpha | -0.06 | Standard Deviation | 0.27 | |
| Beta | 1.30 |
Today's Price Range 0.36070.4120 | 52W Range 0.36112.37 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -26.00% | ||
| 1 Month | -19.51% | ||
| 3 Months | -60.22% | ||
| 6 Months | -55.10% | ||
| 1 Year | -59.03% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | 243.85 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -236.70 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -183.17 | |||
Return on invested Capital Q | -45.48 | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.80 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.60 | ||||
| 1.55 | ||||
| 103.12 | ||||
| - | ||||
| -1.00 | ||||
| -0.63 | ||||
| 2.64 | ||||
| 0.38 | ||||
| 6.49M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.30 | ||||
| 2.50 | ||||
| - | ||||
| - | ||||
| -3.40 | ||||
| Leverage Ratio | 47.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -28.70 | ||||
| -11 255.30 | ||||
| -10 871.80 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 37.92K | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 27.90K |
| Shares Outstanding | 8.20K |
| Shares Float | 5.72M |
| Trades Count | 99 |
| Dollar Volume | 10.89K |
| Avg. Volume | 52.17K |
| Avg. Weekly Volume | 82.35K |
| Avg. Monthly Volume | 32.37K |
| Avg. Quarterly Volume | 41.79K |
Aclarion Inc. (NASDAQ: ACON) stock closed at 0.37 per share at the end of the most recent trading day (a -7.52% change compared to the prior day closing price) with a volume of 27.90K shares and market capitalization of 3.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 6 people. Aclarion Inc. CEO is .
The one-year performance of Aclarion Inc. stock is -59.03%, while year-to-date (YTD) performance is -36.21%. ACON stock has a five-year performance of %. Its 52-week range is between 0.3611 and 2.37, which gives ACON stock a 52-week price range ratio of 0.44%
Aclarion Inc. currently has a PE ratio of -0.60, a price-to-book (PB) ratio of 1.55, a price-to-sale (PS) ratio of 103.12, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -236.70%, a ROC of -183.17% and a ROE of 243.85%. The company’s profit margin is -%, its EBITDA margin is -10 871.80%, and its revenue ttm is $37.92 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aclarion Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aclarion Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aclarion Inc. is — (0), with a target price of $3, which is +710.81% compared to the current price. The earnings rating for Aclarion Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aclarion Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aclarion Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.87, ATR14 : 0.05, CCI20 : -179.70, Chaikin Money Flow : 0.02, MACD : -0.03, Money Flow Index : 24.10, ROC : -22.90, RSI : 34.87, STOCH (14,3) : 6.68, STOCH RSI : 0.00, UO : 47.15, Williams %R : -93.32), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aclarion Inc. in the last 12-months were: Brent Ness (Buy at a value of $9 769), John Lorbiecki (Buy at a value of $10 000)
Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.
CEO:
Telephone: +1 650 241-1741
Address: 951 Mariners Island Boulevard, San Mateo 94404, CA, US
Number of employees: 6
